Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Completed · Phase 2

Conditions studied: Warts

In brief

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks. A second purpose is to evaluate the safety of the drug.

Key facts

Study ID

NCT00116675

Run by

Graceway Pharmaceuticals, LLC

People needed

84

Starts

2005-03-01

Expected to finish

2006-04-01

Last updated by the study team

2007-02-19

Who can join

Age: 3 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of common warts
• Ages between 3 to 11

You may not qualify if…

• Other types of wart(s), ie. plantar
• Currently participating in another clinical study
• Chronic viral hepatitis B or C

Where it is running

• Children's Clinic of Jonesboro, PA — Jonesboro, Arkansas, United States
• University of California - San Francisco — San Francisco, California, United States
• Longmont Clinic/Longmont Medical Research Network — Longmont, Colorado, United States
• Mercy Health Research — St Louis, Missouri, United States
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Rhode Island Hospital - Jane Brown Building — Providence, Rhode Island, United States
• DermResearch, Inc. — Austin, Texas, United States
• Alpine Pediatrics — Pleasant Grove, Utah, United States
• Walla Walla Clinic — Walla Walla, Washington, United States
• Advanced Healthcare — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.